Breaking News Instant updates and real-time market news.

HAS

Hasbro

$87.33

1.24 (1.44%)

, FNKO

Funko

$8.24

-0.12 (-1.44%)

09:42
04/12/18
04/12
09:42
04/12/18
09:42

Hasbro price target lowered to $90 from $102 at SunTrust

SunTrust analyst Michael Swartz lowered his price target on Hasbro (HAS) to $90 citing the impact from the liquidation of Toys R' Us. Swartz says there are several uncertainties in the unwinding process around its duration and spillover impact on the toy makers, though he generally expects the fallout to be felt by Hasbro for the duration of 2018. Among the peers, the analyst is positive on Funko (FNKO), adding that its guidance range has likely already reflected most of the Toys R' Us business going away.

HAS

Hasbro

$87.33

1.24 (1.44%)

FNKO

Funko

$8.24

-0.12 (-1.44%)

  • 23

    Apr

HAS Hasbro
$87.33

1.24 (1.44%)

03/08/18
BMOC
03/08/18
NO CHANGE
Target $96
BMOC
Market Perform
Hasbro price target lowered to $96 from $100 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Hasbro to $96 and kept his Market Perform rating in the wake of last month's annual New York Toy Fair. Johnson writes that while the company has executed well in its "solid strategy", his meetings with the management of the company as well as those of its peers suggest that the U.S. toy market is expected to be flat with some added uncertainty related to the bankruptcy of Toys R Us, evolving retail landscape, and the underperformance of movie toys. The analyst adds that while Hasbro is gaining share with its "new approach to product development", its valuation is at a premium of 17-times forward multiple vs. 15-times historical average.
03/09/18
LEHM
03/09/18
DOWNGRADE
Target $13
LEHM
Underweight
Barclays downgrades Mattel to Underweight on possible Toys R Us liquidation
Barclays analyst Felicia Hendrix downgraded Mattel (MAT) to Underweight from Equal Weight and cut her price target for the shares to $13 from $16. The analyst maintains an Overweight rating on Hasbro (HAS) while trimming her target for the stock to $100 from $110. Mattel faces downside risk from the potential Toys R Us liquidation, Hendrix tells investors in a research note. The company generates 8% of its sales from Toys R Us and its shares are up 4% since reporting earnings on February 1, the analyst notes. She believes sell-side estimates for both Mattel and Hasbro likely only include the closure of 182 Toys R Us U.S. stores. The analyst finds Hasbro's risk/reward more favorable at current share levels.
03/22/18
KEYB
03/22/18
NO CHANGE
Target $110
KEYB
Overweight
Hasbro shares present 'compelling' long-term buying opportunity, says KeyBanc
KeyBanc analyst Brett Andress believes Hasbro shares at current levels present a "compelling" long-term buying opportunity as Toys R Us headline risk fades and investors begin to look into a catalyst-rich FY19. The analyst reiterates an Overweight rating and $110 price target on the stock.
04/06/18
MKMP
04/06/18
NO CHANGE
Target $96
MKMP
Neutral
Hasbro price target lowered to $96 from $110 at MKM Partners
MKM Partners analyst Eric Handler lowered his price target on Hasbro (HAS) to $96, saying the company's earnings will see a bigger impact from the liquidation of Toys R Us than the previous forecast. The analyst also notes headwinds for the company coming from tight inventory management at mass retailers Wal-Mart (WMT) and Amazon (AMZN). Handler adds that he has broader industry concerns, but sees some mitigating product launches for Hasbro, including a new Nerf brand launch, expanded Baby Alive product lines, continued strength from Marvel, and the possible digital launch of Magic: The Gathering Arena. The analyst keeps his Neutral rating on Hasbro.
FNKO Funko
$8.24

-0.12 (-1.44%)

11/27/17
11/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. iRadimed (IRMD) initiated with an Outperform at Credit Suisse. 2. Funko (FNKO) was initiated with a Buy at Goldman Sachs, SunTrust, BofA/Merrill, Jefferies, and Stifel, while being initiated with an Overweight at JPMorgan and an Outperform at BMO Capital. 3. Evoqua Water (AQUA) was initiated with an Outperform at RBC Capital and Raymond James, a Buy at Citi, a Hold at Stifel, as well as a Neutral at Goldman Sachs and Baird. 4. Spero Therapeutics (SPRO) was initiated with an Outperform at Oppenheimer and Cowen, a Buy at Stifel, and a Neutral at BofA/Merrill. 5. Altair (ALTR) was initiated with an Outperform at William Blair, a Buy at Deutsche Bank, a Sector Perform at RBC Capital, a Hold at Canaccord, and a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
BMOC
12/19/17
DOWNGRADE
BMOC
Market Perform
Funko downgraded to Market Perform from Outperform at BMO Capital
12/19/17
BMOC
12/19/17
DOWNGRADE
Target $7.5
BMOC
Market Perform
Funko downgraded to Market Perform at BMO Capital on rising inventory
As noted earlier, BMO Capital Gerrick L. Johnson downgraded Funko to Market Perform from Outperform and lowered his price target to $7.50 from $10. Johnson says his recent channel checks have suggested a build-up in the company's inventory levels at retail locations - particularly the flagship Pop! line - and also a rise in discounting. The analyst believes performance has deteriorated relative to expectations since the company reported Q3 results.
01/17/18
PIPR
01/17/18
NO CHANGE
Target $12
PIPR
Overweight
Funko partnership with Netflix underappreciated, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy remains positive on Funko (FNKO) citing her optimism around the film slate, the "ongoing durability of pop culture" and the stock's "compelling valuation." She also believes the company's partnership with Netflix (NFLX) is being underappreciated by investors. Given the amount of in-demand content being created by Netflix today, Funko is "extremely well positioned from their leading partnership," Murphy tells investors in a research note. The analyst keeps an Overweight rating on Funko with a $12 price target.

TODAY'S FREE FLY STORIES

PCG

PG&E

$25.66

-7.04 (-21.53%)

05:54
11/15/18
11/15
05:54
11/15/18
05:54
Recommendations
PG&E analyst commentary  »

PG&E worried about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEIC

SEI Investments

$53.04

-0.76 (-1.41%)

05:52
11/15/18
11/15
05:52
11/15/18
05:52
Conference/Events
SEI Investments to host analyst conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ED

Consolidated Edison

$79.41

0.275 (0.35%)

05:51
11/15/18
11/15
05:51
11/15/18
05:51
Syndicate
Consolidated Edison 13.6M share Secondary priced at $77.00 »

Citi, Barclays and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

FB

Facebook

$144.25

2.06 (1.45%)

05:49
11/15/18
11/15
05:49
11/15/18
05:49
Periodicals
Facebook ends relationship with Definers Public Affairs, NY Times reports »

Facebook has ended its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HZNP

Horizon Pharma

$21.23

-0.64 (-2.93%)

05:48
11/15/18
11/15
05:48
11/15/18
05:48
Downgrade
Horizon Pharma rating change  »

Horizon Pharma downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

CSIQ

Canadian Solar

$13.73

0.34 (2.54%)

05:47
11/15/18
11/15
05:47
11/15/18
05:47
Earnings
Canadian Solar reports Q3 EPS $1.09 vs. 22c last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SRRA

Sierra Oncology

$1.61

-0.04 (-2.42%)

05:45
11/15/18
11/15
05:45
11/15/18
05:45
Hot Stocks
Sierra Oncology reports preclinical efficacy for SRA737 »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

05:40
11/15/18
11/15
05:40
11/15/18
05:40
Downgrade
Daimler AG rating change  »

Daimler AG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$8.83

-0.15 (-1.67%)

05:39
11/15/18
11/15
05:39
11/15/18
05:39
Hot Stocks
AC Immune awarded third follow-up grant from The Michael J. Fox Foundation »

AC Immune announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

05:38
11/15/18
11/15
05:38
11/15/18
05:38
Hot Stocks
Biohaven enrolls first patient in Phase 3 preventive treatment of migraine trial »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

FB

Facebook

$144.25

2.06 (1.45%)

, AAPL

Apple

$186.81

-5.42 (-2.82%)

05:36
11/15/18
11/15
05:36
11/15/18
05:36
Periodicals
Facebook CEO ordered staff to use Android phones after Apple criticism, NYT says »

Facebook (FB) CEO Mark…

FB

Facebook

$144.25

2.06 (1.45%)

AAPL

Apple

$186.81

-5.42 (-2.82%)

GOOG

Alphabet

$1,043.53

7.2 (0.69%)

GOOGL

Alphabet Class A

$1,054.06

5.52 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

ABBV

AbbVie

$88.28

0.06 (0.07%)

05:29
11/15/18
11/15
05:29
11/15/18
05:29
Hot Stocks
AbbVie signs DUBs collaboration with Mission Therapeutics »

Mission Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$1.07

0.025 (2.39%)

05:26
11/15/18
11/15
05:26
11/15/18
05:26
Earnings
Teekay Tankers reports Q3 adj. EPS (7c), consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ATUS

Altice USA

$17.71

-0.1 (-0.56%)

05:25
11/15/18
11/15
05:25
11/15/18
05:25
Initiation
Altice USA initiated  »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGP

Teekay LNG

$14.41

0.29 (2.05%)

05:23
11/15/18
11/15
05:23
11/15/18
05:23
Earnings
Teekay LNG reports Q3 adj. EPS 16c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SUBCY

Subsea 7

$0.00

(0.00%)

05:22
11/15/18
11/15
05:22
11/15/18
05:22
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EXEL

Exelixis

$16.75

0.09 (0.54%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:20
11/15/18
11/15
05:20
11/15/18
05:20
Hot Stocks
Exelixis receives EC approval for Cabometyx tablets »

Exelixis (EXEL) announced…

EXEL

Exelixis

$16.75

0.09 (0.54%)

IPSEY

Ipsen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 14

    Jan

CTTAY

Continental AG

$0.00

(0.00%)

05:19
11/15/18
11/15
05:19
11/15/18
05:19
Downgrade
Continental AG rating change  »

Continental AG downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VLEEY

Valeo

$0.00

(0.00%)

05:18
11/15/18
11/15
05:18
11/15/18
05:18
Downgrade
Valeo rating change  »

Valeo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,599.16

-32.52 (-1.99%)

05:14
11/15/18
11/15
05:14
11/15/18
05:14
Recommendations
Amazon.com analyst commentary  »

Amazon shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

ATNX

Athenex

$10.28

-1.38 (-11.84%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Upgrade
Athenex rating change  »

Athenex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

STIM

Neuronetics

$18.58

-3.17 (-14.57%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Recommendations
Neuronetics analyst commentary  »

Neuronetics selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVID

Avid

$5.79

0.19 (3.39%)

04:59
11/15/18
11/15
04:59
11/15/18
04:59
Recommendations
Avid analyst commentary  »

Avid price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$153.45

-3.35 (-2.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Initiation
Linde plc initiated  »

Linde plc initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$209.85

2.02 (0.97%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MarketAxess management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.